Use of eVLP-based vaccine candidates to broaden immunity against SARS-CoV-2 variants - VBI Vaccines

Use of eVLP-based vaccine candidates to broaden immunity against SARS-CoV-2 variants

September 30, 2021 |

Use of eVLP-based vaccine candidates to broaden immunity against SARS-CoV-2 variants
bioRxiv
September 2021

View More

May 15, 2023

VBI Vaccines Reports First Quarter 2023 Financial Results

April 25, 2023

VBI Vaccines Appoints Vaughn Himes to Board of Directors

April 4, 2023

VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

March 13, 2023

VBI Vaccines Reports Full Year 2022 Financial Results

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI